LALEAST
NCT03917082
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
Status:
Opening soon
II
Phase
Adjuvant
Line of Therapy
Early Cancer
Disease Stage
Biomarker(s)
HER2-
Investigational
Product
Tamoxifen Citrate
Adjuvant endocrine therapy for two years
Treatment Arms
o standard of care endocrine therapy for two years